Microfluidics

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Clinical specialities #Drug development #Enabling technologies #Flow Cytometry #Genetics / genomes #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead optimisation #Microfluidics #PCR #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Toxicology

Creating vaccines drop by drop

By Richard Gray The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways, not least in the… Read More

#Covid-19 #Exclusive Content

#Academic #Analysis #Assay development optimisation & technology #Business #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Immunology #Lead discovery #Microfluidics #Pharmokinetics #Screening #Therapeutics

Carterra closes financing round for LSA platform

Carterra closes financing round for continued growth of the LSA platform for next generation antibody dscovery. Carterra has closed a $6M round of financing led by Ballast Point Ventures with participation from current investor, Telegraph Hill Partners. The additional funding will support the continued adoption… Read More

#News

#Analysis #Assay development optimisation & technology #Business #Cellular assays #Microfluidics #Patent Law #System biology #Systems biology

Sphere Fluidics expands commercial operations with Pico-Surf

Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics. Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf™, for reliable and… Read More

#News

#Academic #Business #Cell therapy #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Drug target for aggressive breast cancer found

A team of British and American scientists has discovered a way to slow the growth of breast cancer stem cells in the lab. The study led by Dr Bruno Simões and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously… Read More

#Cancer Research #News

#Academic #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Gene therapy #Microfluidics

Technology developed to rapidly scale up cell and gene therapy manufacture

Image: ThisisEngineering RAEng CPI, MicrofluidX and the Cell and Gene Therapy Catapult (CGT Catapult) have collaborated in a project to develop bioprocessing technology for the rapid scale-up of cell and gene therapies. The technology has the potential to overcome a major bottleneck in the development of these novel… Read More

#News

#Academic #Business #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK government advises drug companies to stockpile in case of Brexit disruption

Image: Joshua Coleman According to the Department of Health and Social Care (DHSC), pharmaceutical companies should stockpile six weeks’ worth of goods “to help ensure the continuity of supply of medical goods into and out of the UK”. In a letter to the industry Steve Oldfield, Chief Commercial Officer,… Read More

#Covid-19 #News

#Academic #Biologics / Biotechnology #Business #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Just-Evotec Biologics to make monoclonal antibody products for COVID-19

Image: Ani Kolleshi The US Department of Defence (DOD) has awarded Evotec’s Seattle-based subsidiary, Just-Evotec Biologics a contract worth $18.2 million to develop monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19 Under the contract, Just–Evotec Biologics will design a manufacturing process for the production of Current Good… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cell therapy #Cellular assays #Chemical engineering #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Oncology #RNA #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Merging two immunotherapies may be more effective treatment against some cancers

Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of… Read More

#Cancer Research #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Precision medicine #Preclinical #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

British Patient Capital invests in life-changing biotech companies

British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building… Read More

#Covid-19 #News

#Academic #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Top Ten UK organisations for animal research announced

Understanding Animal Research (UAR), which promotes openness about animal research, has released a list of the ten organisations in Great Britain that carry out the highest number of animal procedures in medical, veterinary and scientific research. These statistics are freely available on the organisations’ websites as part of… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #Therapeutics #Translational #Translational chemistry

Quantro Therapeutics offers breakthrough oncology drug discovery platform

21 July 2020 Image: Anshu A Thanks to seed financing from Boehringer Ingelheim Venture Fund (BIVF) and Evotec, Quantro Therapeutics will generate a drug discovery pipeline, aiming to transform the precision and scope of cell-based compound screens. With the introduction of ‘Transcriptional Fingerprinting’ to drug discovery, Quantro intends… Read More

#News

#Academic #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Protein chemistry / Proteomics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Sphere Fluidics and Heriot-Watt University develop droplet generator instrumentation

20 July 2020 Image: Toa Heftiba Sphere Fluidics and Heriot-Watt University have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency. The grant will facilitate the development of novel droplet generator instrumentation, which will be used to expand Sphere Fluidics’ portfolio of… Read More

#News

#Academic #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK pharma body says COVID-19 vaccine may still be many months away

Image: Dimitri Houtteman A COVID-19 vaccine being developed by Oxford University and AstraZeneca has generated an immune response in a study of roughly 1,000 patients, according to interim results. The Association of the British Pharmaceutical Industry (ABPI) has responded to the results of the Oxford – AstraZeneca vaccine… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell culture #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Merck opens its largest M Lab Collaboration Centre in Shanghai

14 July 2020 Image: Denys Nevozhai Merck has opened its M Lab Collaboration Centre in Shanghai, the largest of the company’s nine centres worldwide. “With the booming pharmaceutical industry in Asia and greater emphasis on novel drug therapies, we see an increase in R&D on leading-edge treatments including… Read More

#News

#Academic #Biomarkers #Business #Cell therapy #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Oncology #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Panthera and Rutherford Health launch oncology clinical trial network

7 July 2020 Rutherford’s independent network currently consists of four cancer treatment centres in Newport, Reading, Bedlington and Liverpool. It will draw patients from all over the UK offering pharma and CROs access to patients through more than 170 referring oncologists. Each of the Rutherford Cancer Centres has… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Microfluidics #Molecular medicine #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Cell ‘membrane on a chip’ could speed up screening of drug candidates for COVID-19

Researchers have developed a human cell ‘membrane on a chip’ that allows continuous monitoring of how drugs and infectious agents interact with our cells. It may soon be used to test potential drug candidates for COVID-19. The researchers, from the University of Cambridge, Cornell University and Stanford University,… Read More

#Covid-19 #News